NASDAQ: MNPRMonopar Therapeutics Stock
$63.58+1.15 (+1.84%)
Updated May 8, 2026
MNPR Price
$63.58
Fair Value Price
N/A
Market Cap
$425.45M
52 Week Low
$28.40
52 Week High
$105.00
P/E
-34.36x
P/B
3.09x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$13.72M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.02
Operating Cash Flow
-$12M
Beta
0.81
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
MNPR Overview
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine MNPR's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
MNPR
Ranked#406 of 458
Ranked#406 of 458
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $225.79 | A | |
| $48.16 | A | |
| $7.49 | A |
Be the first to know about important MNPR news, forecast changes, insider trades & much more!
MNPR News
Overview
Due Diligence Score
–
Industry Average (25)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MNPR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MNPR is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
MNPR is good value based on its book value relative to its share price (3.09x), compared to the US Biotechnology industry average (4.99x)
P/B vs Industry Valuation
MNPR is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more MNPR due diligence checks available for Premium users.
Valuation
MNPR fair value
Fair Value of MNPR stock based on Discounted Cash Flow (DCF)
Price
$63.58
Fair Value
$3.99
Overvalued by
1,493.58%
MNPR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
MNPR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-34.36x
Industry
16.15x
Market
23.09x
MNPR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.09x
Industry
4.99x
MNPR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MNPR's financial health
Profit margin
Revenue
$0.0
Net Income
-$5.2M
Profit Margin
0%
MNPR's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$140.7M
Liabilities
$2.9M
Debt to equity
0.02
MNPR's short-term assets ($140.46M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MNPR's short-term assets ($140.46M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MNPR's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
MNPR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.4M
Investing
-$62.2M
Financing
-$384.7k
MNPR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MNPR vs Biotech Stocks
Monopar Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.